OrbiMed Advisors acquires 500,000 shares at $4.00 for $2,000,000.00, increasing stake as company fights unprofitability
OrbiMed Advisors, a 10% owner of scPharmaceuticals, executed 2 separate purchases totaling 500,000 shares for $2,000,000.00 at a blended average price of $4.00 per share. The transaction occurred when the stock was trading at $5.06, 36.4% below its 52-week high of $7.96. The purchase is material in absolute size, but comes amid significant operational challenges: scPharmaceuticals reported quarterly revenue of $8.1M against a net loss of $17.1M, and was unprofitable over its most recent full fiscal year. OrbiMed's cross-ticker track record shows 9 prior buys with a 66.67% 90-day win rate and average 90-day return of +578.1%, though same-ticker measurable history is not provided. The timing of this substantial accumulation warrant careful attention to whether this reflects continued confidence in company recovery strategy or portfolio positioning independent of near-term fundamentals.